|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARHGAP22 |
Gene summary for ARHGAP22 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARHGAP22 | Gene ID | 58504 |
| Gene name | Rho GTPase activating protein 22 | |
| Gene Alias | RhoGAP2 | |
| Cytomap | 10q11.22-q11.23 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | Q7Z5H3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 58504 | ARHGAP22 | PTC07 | Human | Thyroid | PTC | 3.99e-08 | 1.32e-01 | 0.2044 |
| 58504 | ARHGAP22 | ATC11 | Human | Thyroid | ATC | 9.20e-14 | 9.95e-01 | 0.3386 |
| 58504 | ARHGAP22 | ATC12 | Human | Thyroid | ATC | 1.65e-14 | 3.24e-01 | 0.34 |
| 58504 | ARHGAP22 | ATC3 | Human | Thyroid | ATC | 5.41e-25 | 1.26e+00 | 0.338 |
| 58504 | ARHGAP22 | ATC4 | Human | Thyroid | ATC | 3.44e-20 | 3.92e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005105617 | Thyroid | PTC | regulation of small GTPase mediated signal transduction | 132/5968 | 302/18723 | 9.26e-06 | 1.04e-04 | 132 |
| GO:004308718 | Thyroid | PTC | regulation of GTPase activity | 148/5968 | 348/18723 | 1.63e-05 | 1.71e-04 | 148 |
| GO:00991738 | Thyroid | PTC | postsynapse organization | 77/5968 | 168/18723 | 1.01e-04 | 8.25e-04 | 77 |
| GO:00991754 | Thyroid | PTC | regulation of postsynapse organization | 45/5968 | 90/18723 | 2.57e-04 | 1.84e-03 | 45 |
| GO:004354714 | Thyroid | PTC | positive regulation of GTPase activity | 103/5968 | 255/18723 | 2.38e-03 | 1.25e-02 | 103 |
| GO:00508089 | Thyroid | PTC | synapse organization | 161/5968 | 426/18723 | 5.11e-03 | 2.36e-02 | 161 |
| GO:00508074 | Thyroid | PTC | regulation of synapse organization | 84/5968 | 211/18723 | 8.72e-03 | 3.64e-02 | 84 |
| GO:00508032 | Thyroid | PTC | regulation of synapse structure or activity | 86/5968 | 218/18723 | 1.05e-02 | 4.23e-02 | 86 |
| GO:005105618 | Thyroid | ATC | regulation of small GTPase mediated signal transduction | 141/6293 | 302/18723 | 1.43e-06 | 1.77e-05 | 141 |
| GO:004308719 | Thyroid | ATC | regulation of GTPase activity | 153/6293 | 348/18723 | 3.24e-05 | 2.68e-04 | 153 |
| GO:009917314 | Thyroid | ATC | postsynapse organization | 78/6293 | 168/18723 | 3.66e-04 | 2.26e-03 | 78 |
| GO:009917512 | Thyroid | ATC | regulation of postsynapse organization | 44/6293 | 90/18723 | 1.89e-03 | 9.27e-03 | 44 |
| GO:004354715 | Thyroid | ATC | positive regulation of GTPase activity | 106/6293 | 255/18723 | 4.58e-03 | 1.89e-02 | 106 |
| GO:005080712 | Thyroid | ATC | regulation of synapse organization | 87/6293 | 211/18723 | 1.20e-02 | 4.27e-02 | 87 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARHGAP22 | SNV | Missense_Mutation | rs754912116 | c.2036G>A | p.Arg679Gln | p.R679Q | Q7Z5H3 | protein_coding | deleterious(0.02) | probably_damaging(0.99) | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ARHGAP22 | deletion | Frame_Shift_Del | c.479delC | p.Pro160LeufsTer2 | p.P160Lfs*2 | Q7Z5H3 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| ARHGAP22 | SNV | Missense_Mutation | rs781379645 | c.598C>T | p.Arg200Trp | p.R200W | Q7Z5H3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-4N-A93T-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | SD |
| ARHGAP22 | SNV | Missense_Mutation | c.1244N>T | p.Ala415Val | p.A415V | Q7Z5H3 | protein_coding | tolerated(0.29) | benign(0.09) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ARHGAP22 | SNV | Missense_Mutation | c.926N>G | p.Glu309Gly | p.E309G | Q7Z5H3 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ARHGAP22 | SNV | Missense_Mutation | rs372857506 | c.604N>T | p.Arg202Cys | p.R202C | Q7Z5H3 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ARHGAP22 | SNV | Missense_Mutation | novel | c.1654G>A | p.Asp552Asn | p.D552N | Q7Z5H3 | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ARHGAP22 | SNV | Missense_Mutation | c.1986N>T | p.Lys662Asn | p.K662N | Q7Z5H3 | protein_coding | deleterious(0) | benign(0.295) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ARHGAP22 | SNV | Missense_Mutation | c.551N>C | p.Gly184Ala | p.G184A | Q7Z5H3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| ARHGAP22 | SNV | Missense_Mutation | rs762382896 | c.842N>A | p.Gly281Asp | p.G281D | Q7Z5H3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |